Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma
Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We...
Gespeichert in:
| Veröffentlicht in: | Journal of Veterinary Medical Science 2024, Vol.86(10), pp.1100-1104 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1104 |
|---|---|
| container_issue | 10 |
| container_start_page | 1100 |
| container_title | Journal of Veterinary Medical Science |
| container_volume | 86 |
| creator | SAKUMA, Hiroki TANI, Akiyoshi GOTO-KOSHINO, Yuko OHMI, Aki TSUJIMOTO, Hajime TOMIYASU, Hirotaka |
| description | Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We administered vincristine to nine CHS cases that acquired resistance to lomustine or nimustine. Complete remission was achieved in one dog, partial remission in two dogs, stable disease in five dogs, and progressive disease in one dog. The median progression-free survival was 21 days (range: 7–71 days). Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS. |
| doi_str_mv | 10.1292/jvms.24-0218 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11442396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3128502813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-b3becd5090ef2f57d45215c6c0755be640f0f58f27fc270d03f0b9695b25b9113</originalsourceid><addsrcrecordid>eNpdkUtrGzEURkVJaZy0u66LIJsuMqmeM9IqBJNHS6Cbdi0011IsMzNypBmD_3012DVNN1eL73C4Vx9Cnym5oUyzb5tdn2-YqAij6h1aUC6aqhFcn6EF0bSuGibJObrIeUMKImr9AZ1zTbWiSi3Qj3vvA1jY4-jxLgyQQh7D4LDN2OLkMkwOj2uX7HaPfUwY7DDH6xmLsB8D4GwTxN5-RO-97bL7dHwv0e-H-1_Lp-r55-P35d1zBULxsWp562AliSbOMy-blZCMSqiBNFK2rhbEEy-VZ40H1pAV4Z60utayZbLVlPJLdHvwbqe2dytww5hsZ7Yp9DbtTbTBvE2GsDYvcWcoFYJxXRfD16MhxdfJ5dH0IYPrOju4OGXDidZUENnogl79h27ilIZyn-GUKUmYorxQ1wcKUsw5OX_ahhIzt2TmlgwTZm6p4F_-veAE_62lAMsDsMmjfXEnwKby35072FQ928s8ak8prG0ybuB_AIVnpnw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128502813</pqid></control><display><type>article</type><title>Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>SAKUMA, Hiroki ; TANI, Akiyoshi ; GOTO-KOSHINO, Yuko ; OHMI, Aki ; TSUJIMOTO, Hajime ; TOMIYASU, Hirotaka</creator><creatorcontrib>SAKUMA, Hiroki ; TANI, Akiyoshi ; GOTO-KOSHINO, Yuko ; OHMI, Aki ; TSUJIMOTO, Hajime ; TOMIYASU, Hirotaka</creatorcontrib><description>Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We administered vincristine to nine CHS cases that acquired resistance to lomustine or nimustine. Complete remission was achieved in one dog, partial remission in two dogs, stable disease in five dogs, and progressive disease in one dog. The median progression-free survival was 21 days (range: 7–71 days). Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS.</description><identifier>ISSN: 0916-7250</identifier><identifier>ISSN: 1347-7439</identifier><identifier>EISSN: 1347-7439</identifier><identifier>DOI: 10.1292/jvms.24-0218</identifier><identifier>PMID: 39198188</identifier><language>eng</language><publisher>Japan: JAPANESE SOCIETY OF VETERINARY SCIENCE</publisher><subject>Animals ; Antineoplastic Agents, Phytogenic - therapeutic use ; Chemotherapy ; Dendritic cells ; Disease resistance ; dog ; Dog Diseases - drug therapy ; Dogs ; Drug Resistance, Neoplasm ; Female ; histiocytic sarcoma ; Histiocytic Sarcoma - drug therapy ; Histiocytic Sarcoma - veterinary ; Internal Medicine ; Lomustine - therapeutic use ; Macrophages ; Male ; Nimustine - therapeutic use ; Prospective Studies ; Remission ; Sarcoma ; Thrombocytopenia ; Vincristine ; Vincristine - therapeutic use</subject><ispartof>Journal of Veterinary Medical Science, 2024, Vol.86(10), pp.1100-1104</ispartof><rights>2024 by the Japanese Society of Veterinary Science</rights><rights>2024. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 The Japanese Society of Veterinary Science 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c483t-b3becd5090ef2f57d45215c6c0755be640f0f58f27fc270d03f0b9695b25b9113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442396/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442396/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39198188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SAKUMA, Hiroki</creatorcontrib><creatorcontrib>TANI, Akiyoshi</creatorcontrib><creatorcontrib>GOTO-KOSHINO, Yuko</creatorcontrib><creatorcontrib>OHMI, Aki</creatorcontrib><creatorcontrib>TSUJIMOTO, Hajime</creatorcontrib><creatorcontrib>TOMIYASU, Hirotaka</creatorcontrib><title>Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma</title><title>Journal of Veterinary Medical Science</title><addtitle>J. Vet. Med. Sci.</addtitle><description>Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We administered vincristine to nine CHS cases that acquired resistance to lomustine or nimustine. Complete remission was achieved in one dog, partial remission in two dogs, stable disease in five dogs, and progressive disease in one dog. The median progression-free survival was 21 days (range: 7–71 days). Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS.</description><subject>Animals</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Chemotherapy</subject><subject>Dendritic cells</subject><subject>Disease resistance</subject><subject>dog</subject><subject>Dog Diseases - drug therapy</subject><subject>Dogs</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>histiocytic sarcoma</subject><subject>Histiocytic Sarcoma - drug therapy</subject><subject>Histiocytic Sarcoma - veterinary</subject><subject>Internal Medicine</subject><subject>Lomustine - therapeutic use</subject><subject>Macrophages</subject><subject>Male</subject><subject>Nimustine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Remission</subject><subject>Sarcoma</subject><subject>Thrombocytopenia</subject><subject>Vincristine</subject><subject>Vincristine - therapeutic use</subject><issn>0916-7250</issn><issn>1347-7439</issn><issn>1347-7439</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtrGzEURkVJaZy0u66LIJsuMqmeM9IqBJNHS6Cbdi0011IsMzNypBmD_3012DVNN1eL73C4Vx9Cnym5oUyzb5tdn2-YqAij6h1aUC6aqhFcn6EF0bSuGibJObrIeUMKImr9AZ1zTbWiSi3Qj3vvA1jY4-jxLgyQQh7D4LDN2OLkMkwOj2uX7HaPfUwY7DDH6xmLsB8D4GwTxN5-RO-97bL7dHwv0e-H-1_Lp-r55-P35d1zBULxsWp562AliSbOMy-blZCMSqiBNFK2rhbEEy-VZ40H1pAV4Z60utayZbLVlPJLdHvwbqe2dytww5hsZ7Yp9DbtTbTBvE2GsDYvcWcoFYJxXRfD16MhxdfJ5dH0IYPrOju4OGXDidZUENnogl79h27ilIZyn-GUKUmYorxQ1wcKUsw5OX_ahhIzt2TmlgwTZm6p4F_-veAE_62lAMsDsMmjfXEnwKby35072FQ928s8ak8prG0ybuB_AIVnpnw</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>SAKUMA, Hiroki</creator><creator>TANI, Akiyoshi</creator><creator>GOTO-KOSHINO, Yuko</creator><creator>OHMI, Aki</creator><creator>TSUJIMOTO, Hajime</creator><creator>TOMIYASU, Hirotaka</creator><general>JAPANESE SOCIETY OF VETERINARY SCIENCE</general><general>Japan Science and Technology Agency</general><general>The Japanese Society of Veterinary Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240101</creationdate><title>Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma</title><author>SAKUMA, Hiroki ; TANI, Akiyoshi ; GOTO-KOSHINO, Yuko ; OHMI, Aki ; TSUJIMOTO, Hajime ; TOMIYASU, Hirotaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-b3becd5090ef2f57d45215c6c0755be640f0f58f27fc270d03f0b9695b25b9113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Chemotherapy</topic><topic>Dendritic cells</topic><topic>Disease resistance</topic><topic>dog</topic><topic>Dog Diseases - drug therapy</topic><topic>Dogs</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>histiocytic sarcoma</topic><topic>Histiocytic Sarcoma - drug therapy</topic><topic>Histiocytic Sarcoma - veterinary</topic><topic>Internal Medicine</topic><topic>Lomustine - therapeutic use</topic><topic>Macrophages</topic><topic>Male</topic><topic>Nimustine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Remission</topic><topic>Sarcoma</topic><topic>Thrombocytopenia</topic><topic>Vincristine</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SAKUMA, Hiroki</creatorcontrib><creatorcontrib>TANI, Akiyoshi</creatorcontrib><creatorcontrib>GOTO-KOSHINO, Yuko</creatorcontrib><creatorcontrib>OHMI, Aki</creatorcontrib><creatorcontrib>TSUJIMOTO, Hajime</creatorcontrib><creatorcontrib>TOMIYASU, Hirotaka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Veterinary Medical Science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SAKUMA, Hiroki</au><au>TANI, Akiyoshi</au><au>GOTO-KOSHINO, Yuko</au><au>OHMI, Aki</au><au>TSUJIMOTO, Hajime</au><au>TOMIYASU, Hirotaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma</atitle><jtitle>Journal of Veterinary Medical Science</jtitle><addtitle>J. Vet. Med. Sci.</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>86</volume><issue>10</issue><spage>1100</spage><epage>1104</epage><pages>1100-1104</pages><artnum>24-0218</artnum><issn>0916-7250</issn><issn>1347-7439</issn><eissn>1347-7439</eissn><abstract>Canine histiocytic sarcoma (CHS) is a malignant tumor derived from macrophages and dendritic cells. Since effective chemotherapy is needed for CHS cases, we conducted this prospective study to evaluate the efficacy and adverse events of vincristine treatment as a rescue therapy for this disease. We administered vincristine to nine CHS cases that acquired resistance to lomustine or nimustine. Complete remission was achieved in one dog, partial remission in two dogs, stable disease in five dogs, and progressive disease in one dog. The median progression-free survival was 21 days (range: 7–71 days). Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS.</abstract><cop>Japan</cop><pub>JAPANESE SOCIETY OF VETERINARY SCIENCE</pub><pmid>39198188</pmid><doi>10.1292/jvms.24-0218</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0916-7250 |
| ispartof | Journal of Veterinary Medical Science, 2024, Vol.86(10), pp.1100-1104 |
| issn | 0916-7250 1347-7439 1347-7439 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11442396 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Animals Antineoplastic Agents, Phytogenic - therapeutic use Chemotherapy Dendritic cells Disease resistance dog Dog Diseases - drug therapy Dogs Drug Resistance, Neoplasm Female histiocytic sarcoma Histiocytic Sarcoma - drug therapy Histiocytic Sarcoma - veterinary Internal Medicine Lomustine - therapeutic use Macrophages Male Nimustine - therapeutic use Prospective Studies Remission Sarcoma Thrombocytopenia Vincristine Vincristine - therapeutic use |
| title | Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T20%3A01%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20vincristine%20as%20a%20rescue%20therapy%20for%20canine%20histiocytic%20sarcoma&rft.jtitle=Journal%20of%20Veterinary%20Medical%20Science&rft.au=SAKUMA,%20Hiroki&rft.date=2024-01-01&rft.volume=86&rft.issue=10&rft.spage=1100&rft.epage=1104&rft.pages=1100-1104&rft.artnum=24-0218&rft.issn=0916-7250&rft.eissn=1347-7439&rft_id=info:doi/10.1292/jvms.24-0218&rft_dat=%3Cproquest_pubme%3E3128502813%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128502813&rft_id=info:pmid/39198188&rfr_iscdi=true |